The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Nippon Express has provided a pharmaceutical distribution platform with strict temperature control in two ranges -- 2 C to 8 C
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
The plant is expected to start commercial operations from Q4FY24
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The company also plans to expand the facility
Subscribe To Our Newsletter & Stay Updated
